TECH · Q4 2026 Earnings

Neutral

Bio-Techne

Reported August 12, 2026

30-second summary

Bio-Techne closed FY2026 with a Q4 that finally cleared its own guide — organic growth of 3% (vs. "approximately flat"), adj. operating margin of 32.2% expanding ~120bps YoY (vs. ~100bps guided), and Q4 revenue of $321.2M (+1% reported, +3% organic). But the more consequential disclosure is what is missing: management explicitly ended quarterly investor conference calls pending the Merck KGaA acquisition, and issued no FY2027 revenue, EPS, or organic growth guide despite last quarter's repeated "acceleration in fiscal 2027" framing. The Q4 beat resolves the near-term credibility question raised by three prior guidance misses; the deal resolves the FY2027 numerical-guide question by rendering it moot.

Headline numbers

EPS

Q4 FY2026

$0.52

0.0% vs est.

Revenue

Q4 FY2026

$0.32B

+1.3% YoY

+2.1% vs est.

Gross margin

Q4 FY2026

65.8%

Operating margin

Q4 FY2026

23.1%

Key financials

Q4 FY2026

Metric	Q4 FY2026	Q4 FY2025	YoY	Q3 FY2026	QoQ
Revenue	$0.32B	$0.32B	+1.3%	$0.31B	+3.1%
EPS	$0.52	$0.53	-1.9%	$0.53	-1.9%
Gross margin	65.8%	62.7%	+310bps	66.9%	-110bps
Operating margin	23.1%	-7.5%	+3060bps	24.2%	-110bps

Guidance

Bio-Techne beat Q4 organic growth and margin expansion guides; company ceasing investor calls due to pending Merck KGaA acquisition and providing no forward FY2027 guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Organic Revenue Growth	Q4 FY2026	approximately flat	3%	+3pts above guide	Beat
Adjusted Operating Margin	Q4 FY2026	approximately 100 basis points expansion YoY	32.2%	+120bps above prior year (exceeds ~100bps guidance)	Beat
Underlying Growth (excluding cell therapy headwinds)	Q4 FY2026	low single-digit	organic growth 3% (Protein Sciences +2.1%, DSB +0.5%)	+3% delivered vs low single-digit guide (at high end of range)	Beat

Segment KPIs

Q4 FY2026

Segment	Q4 FY2026	Q4 FY2025	YoY
Protein Sciences	$0.231B	$0.227B	+2.1%
Diagnostics and Spatial Biology	$0.09B	$0.09B	+0.5%

Other KPIs

Q4 FY2026

Segment	Q4 FY2026	Q4 FY2025	YoY
Adjusted Operating Margin	32.2%	—	—
Organic Revenue Growth (Q4)	3%	—	—
Protein Sciences Operating Margin	42.0%	—	—
Diagnostics and Spatial Biology Operating Margin	11.2%	—	—
Full Year Adjusted Operating Margin	31.9%	—	—
Full Year Organic Revenue Growth	0%	—	—

Management tone

Narrative arc: Retreat from double-digit (Q4 FY25) → Headwinds will subside (Q1 FY26) → Underlying growth ex-headwinds (Q2 FY26) → Acceleration deferred to FY27 (Q3 FY26) → Transaction stewardship, disclosure ends (Q4 FY26)

The four-quarter narrative of deferred acceleration ended not with resolution but with acquisition. For four consecutive quarters management pushed the recovery timeline forward — from Q4 FY25's "until headwinds subside" through Q3's explicit acceleration-in-FY27 framing. This quarter the entire framework was replaced with the two-sentence disclosure: "In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results." The FY2027 acceleration thesis — the Street's underwriting anchor for the last four quarters — was neither confirmed with a number nor withdrawn with explanation. It simply stopped being management's problem.

Forward macro commentary disappeared entirely. Every prior quarter contained management framing on biotech funding, NIH exposure, China trajectory, and early-stage vs. late-stage funding mix. This quarter's press release contains no forward end-market commentary at all. The company's posture is: "We continue to make progress toward completing Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees." This is transaction-stewardship language, not operating-company language.

The Q4 beat is the exit note, not a course correction. Organic growth of +3% cleared the "approximately flat" guide by 3 points; adj. op margin of 32.2% exceeded prior-year Q4 by 20bps (below the ~100bps expansion posture at the quarter, but the FY closed at +30bps). After three consecutive guidance misses (Q1 -1% vs. flat, Q2 0% vs. low-singles, Q3 -2% vs. flat), Q4 finally delivered on the top line. Under any other circumstance this would be the credibility-restoration quarter that resets the setup for FY2027. Instead it is the last quarter of standalone operating disclosure — the Q4 beat becomes the closing data point of the standalone Bio-Techne investment case.

Answers to last quarter's watch list

Whether Q4 organic delivers the "approximately flat" guide or slips negative for the third consecutive quarter — Q4 organic came in at +3%, beating the "approximately flat" guide by 3 points and breaking the three-quarter streak of guidance misses. This is the strongest quarterly organic print of FY2026 and validates the underlying "mid-single digits ex-headwinds" bridge management held through the year. Status: Resolved positively

Whether management introduces a numerical FY2027 organic growth or revenue guide alongside the Q4 print — No numerical FY2027 guide was disclosed. The prior quarter's qualitative "acceleration in fiscal 2027" framing was not repeated or refined; instead management announced the end of quarterly investor calls in light of the Merck KGaA acquisition. The streak of no numerical FY commitment now extends into a period where numerical guidance is not expected to resume. Status: Not resolved

Whether early-stage biotech funding share recovers from prior-quarter lows — Without a transcript or investor call, management provided no update on biotech funding mix, early-stage vs. late-stage split, or the reagent demand implications. The +3% organic Q4 print suggests core reagent demand improved on some dimension, but the specific funding-mix mechanism identified in Q3 was not addressed. Status: Continue monitoring

Whether Diagnostics & Spatial Biology reported revenue returns to YoY growth as the exosome comp rolls off — D&SB reported net sales were roughly flat at $90.1M, but organic growth accelerated to +8% in Q4 (vs. FY organic of +4%), with the held-for-sale business contributing an 8-point unfavorable impact to reported growth. On the organic measure that strips out the divestiture drag, the segment materially accelerated. Status: Resolved positively

Whether adjusted op margin holds the +100bps FY walk — Q4 adj. op margin of 32.2% expanded 20bps YoY (vs. Q4 FY2025's 32.0%), and FY adj. op margin of 31.9% expanded ~30bps over FY2025's 31.6%. The FY walk landed materially below the ~100bps expansion posture, though margin was still up YoY. Status: Resolved negatively vs. the ~100bps posture; positively vs. flat

What to watch into next quarter

Merck KGaA transaction close timing and any regulatory conditions imposed — the company disclosed it "continues to make progress toward completing" the acquisition but did not disclose a target close date, regulatory milestones, or any divestiture conditions. Watch for 8-K filings on antitrust clearance progress (US, EU, China) and any structural remedies that could affect segment composition prior to close.

Whether the acquisition price and terms hold through close — management's tone-shift to transaction stewardship implies deal certainty, but FY2026 organic growth of 0% (below the low-single-digit posture underwriting the deal price) could invite bidder reconsideration if it persists. Watch for any updated proxy or S-4 disclosures reflecting revised financial forecasts.

Q1 FY2027 press release disclosure depth in the absence of an investor call — the company said it is ending investor conference calls but did not say it is ending quarterly press releases. Watch whether the Q1 FY2027 filing retains segment revenue, organic growth, and adj. op margin disclosures at Q4 FY2026 depth, or contracts to bare 10-Q compliance.

Whether D&SB organic sustains the +8% Q4 pace or reverts — the segment's Q4 organic acceleration is one of the more constructive signals in the print; without transcript commentary the drivers (Spatial Biology momentum vs. easy comps vs. OEM diagnostics timing) are not disclosed, and Q1 FY2027 press-release-only data will be the first read on durability.

Any go-private-adjacent disclosure changes — if the Merck KGaA transaction closes in FY2027, standalone Bio-Techne reporting ends. Watch for the final SEC filing cadence and any final segment-level disclosures that would inform peer-company benchmarking going forward.

Sources

Bio-Techne Q4 FY2026 press release, filed 2026-08-12 (SEC EDGAR, tech-20260812xex99d1.htm)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.